Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x100px

Document › Details

Basilea Pharmaceutica Ltd.. (6/2/17). "Press Release: Basilea Names New Member of Its Extended Management Committee". Basel.

	Organisation	Basilea Pharmaceutica Ltd. (SIX: BSLN)
	Group	Basilea (Group)
	Organisation 2	Novartis Pharma AG
	Group	Novartis (Group)
	Product	antibiotic
	Product 2	cancer drug
	Person	Heller, Damian (Basilea 201708– General Counsel + Corp Secretary joined 2015 before Novartis Pharma + Syngenta)
	Person 2	Scott, Ronald (Ron) (Basilea 201212–201804 CEO before COO before CFO RETIRED 2/18 proposed for Board)

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced that, as of August 1, 2017, Damian Heller will assume the role of General Counsel & Corporate Secretary and join the Extended Management Committee which reports to the CEO. Mr. Heller succeeds Elizabeth Rozek who will be leaving Basilea to relocate to the United States.

Mr. Heller joined Basilea in 2015 as Deputy General Counsel and Global Compliance Officer. Prior to joining Basilea, he served as Global Compliance Officer at Novartis Pharma AG, Corporate Secretary of Syngenta AG and Director of the Basel Institute on Governance.

Mr. Heller holds a master's degree in Law from the University of Basel and a master's degree in Business Administration from the University of Rochester, New York, USA.

Ronald Scott, Basilea's Chief Executive Officer, commented: "We are very pleased that Mr. Heller will assume the role of General Counsel & Corporate Secretary. Damian's knowledge and broad experience in all aspects of pharmaceutical industry law and compliance will be an asset to Basilea. Ms. Rozek joined Basilea as counsel in 2010 and has served as General Counsel & Corporate Secretary since 2011. We wish to sincerely thank Elizabeth for her commitment and valuable contributions to Basilea's success during these years."

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address the medical problem of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102
media_relations@basilea.com
investor_relations@basilea.com

Record changed: 2023-06-05